Study of Investigational Drug in Osteoporosis (MK-0217-908)
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of an investigational drug
in postmenopausal women with osteoporosis. The primary hypothesis of this study is that in
postmenopausal women with osteoporosis, oral monthly ibandronate, at doses of 100 mg and 150
mg, does not achieve persistence in reduction of bone resorption throughout the monthly
dosing interval, as demonstrated by a larger change in the serum carboxyterminal crosslinked
telopeptide of Type I collagen (CTX-I) log-transformed fraction from baseline four weeks post
dose compared to one week post dose, during the third month of treatment, in the participants
taking ibandronate than in the participants taking placebo.